Cargando…
Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands...
Autores principales: | Yoon, Somy, Eom, Gwang Hyeon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chonnam National University Medical School
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976774/ https://www.ncbi.nlm.nih.gov/pubmed/32021836 http://dx.doi.org/10.4068/cmj.2020.56.1.6 |
Ejemplares similares
-
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016) -
Heart failure with preserved ejection fraction: present status and future directions
por: Yoon, Somy, et al.
Publicado: (2019) -
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019) -
Nitrosative Stress and Human Disease: Therapeutic Potential of Denitrosylation
por: Yoon, Somy, et al.
Publicado: (2021) -
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
por: Brown, Michael P, et al.
Publicado: (2019)